English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Breast cancer is the neoplasm with the highest incidence and mortality among   women in Lithuania. The aim of the study was to determine the mutational   incidence in BRCA1 and BRCA2 genes in high-risk breast and/or ovarian cancer   families. After written informed consent, 36 participants from Lithuanian   health science university hospital provided a blood sample for genetic   analysis. Molecular diagnostics was done for 6 BRCA1and BRCA2 mutations. From   36 tested subjects for BRCA1/BRCA2 mutations. Positive test for BRCA1/BRCA2   mutations test was found in 12 (33%) cases. Most common BRCA1 mutation was   5328insC - 6 (50%) cases, other mutations: 185delAG - 1 (8,3%), 300t>6(c61G)   - 4 (33,3%), 4153 del A - 1 (8,3%). All mutations were BRCA1, but none of the   women were positive for the analyzed BRCA2 mutation. The mean age when the   cancer was diagnosed in BRCA1 mutations group was 40.40±3.39 comparing with   the group without mutations - 43.29 ±2.52. Rates of BRCA1 and BRCA2 mutation   testing are increasing in young women with breast and ovarian cancer.   Detected mutations in BRCA1 contribute to up to one-third of the families   with breast and ovarian cancer in Lithuania

The spectrum of the most common BRCA1/BRCA2 mutations in Lithuanian high risk families